CFDE Data Portal | Search LOC105372401

	Label	Description
	LOC105372401 Gene (Entity type)	ENSG00000286177 - uncharacterized LOC105372401
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE206931 WDR5 inhibition WIN 3 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119007 prostaglandin TS-A clone E2 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE99875 everolimus 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE184892 trehalose fibroblast 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 neratinib OVCAR-8 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC105372401

ENSG00000286177 - uncharacterized LOC105372401

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE77108 saha 4 v 7 human up

A Gene Set from LINCS

GSE206931 WDR5 inhibition WIN 3 v 6 human up

A Gene Set from LINCS

GSE119007 prostaglandin TS-A clone E2 1 v 0 human up

A Gene Set from LINCS

GSE99875 everolimus 2 v 0 human dn

A Gene Set from LINCS

GSE184892 trehalose fibroblast 7 v 1 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 6 human dn

A Gene Set from LINCS

GSE128730 neratinib OVCAR-8 4 v 5 human dn

A Gene Set from LINCS

GSE146982 metformin 0 v 6 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.